ZA828048B - Novel anti-cancer drugs for the treatment of leukaemias t constituted by the chain a of ricin and a specific monoclonal antibody - Google Patents

Novel anti-cancer drugs for the treatment of leukaemias t constituted by the chain a of ricin and a specific monoclonal antibody

Info

Publication number
ZA828048B
ZA828048B ZA828048A ZA828048A ZA828048B ZA 828048 B ZA828048 B ZA 828048B ZA 828048 A ZA828048 A ZA 828048A ZA 828048 A ZA828048 A ZA 828048A ZA 828048 B ZA828048 B ZA 828048B
Authority
ZA
South Africa
Prior art keywords
chain
monoclonal antibody
constituted
leukaemias
ricin
Prior art date
Application number
ZA828048A
Other languages
English (en)
Inventor
Pierre Casellas
Pierre Gros
Franz Jansen
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of ZA828048B publication Critical patent/ZA828048B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061Blood cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817Toxins
    • A61K47/6819Plant toxins
    • A61K47/6825Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
    • A61K47/6827Ricin A
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6867Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of a blood cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/866Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Botany (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA828048A 1981-11-20 1982-11-03 Novel anti-cancer drugs for the treatment of leukaemias t constituted by the chain a of ricin and a specific monoclonal antibody ZA828048B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8121836A FR2516794B1 (fr) 1981-11-20 1981-11-20 Nouveaux medicaments anticancereux pour le traitement des leucemies t constitues de la chaine a de la ricine et d'un anticorps monoclonal specifique

Publications (1)

Publication Number Publication Date
ZA828048B true ZA828048B (en) 1983-08-31

Family

ID=9264235

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA828048A ZA828048B (en) 1981-11-20 1982-11-03 Novel anti-cancer drugs for the treatment of leukaemias t constituted by the chain a of ricin and a specific monoclonal antibody

Country Status (10)

Country Link
US (2) US4643895A (ja)
EP (1) EP0080401B1 (ja)
JP (1) JPS58135821A (ja)
AT (1) ATE78699T1 (ja)
AU (1) AU561660B2 (ja)
CA (1) CA1209472A (ja)
DE (1) DE3280408T2 (ja)
FR (1) FR2516794B1 (ja)
NZ (1) NZ202563A (ja)
ZA (1) ZA828048B (ja)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2536997B1 (fr) * 1982-03-11 1987-08-07 Sanofi Sa Medicaments cytotoxiques comportant au moins une immunotoxine et de la methylamine
FR2523445A1 (fr) * 1982-03-17 1983-09-23 Sanofi Sa Nouveaux conjugues associant, par liaison covalente, une enzyme et un anticorps, et associations medicamenteuses utilisant lesdits conjugues
US4520226A (en) * 1982-07-19 1985-05-28 The United States Of America As Represented By The Department Of Health And Human Services Treatment of graft versus host disease using a mixture of T-lymphocyte specific monoclonal antibody: ricin conjugates
GB2137210B (en) * 1983-03-30 1986-11-19 Lilly Industries Ltd Immunoglobulin conjugates
US4664911A (en) * 1983-06-21 1987-05-12 Board Of Regents, University Of Texas System Immunotoxin conjugates employing toxin B chain moieties
FR2547731A1 (fr) * 1983-06-27 1984-12-28 Centre Nat Rech Scient Immunotoxine antitumorale, preparations pharmaceutiques la contenant et son utilisation in vitro
FR2550944B1 (fr) * 1983-08-23 1985-12-06 Sanofi Sa Association pharmaceutique a base d'anticorps anticellules tumorales et de conjugues cytotoxiques, appropriee notamment pour le traitement des cancers
ATE60233T1 (de) * 1983-09-15 1991-02-15 Univ Leland Stanford Junior Allotransplantat mit verminderter immunogenitaet und verfahren und reagenz fuer seine herstellung.
FR2564839B1 (fr) * 1984-05-23 1986-11-14 Sanofi Sa Conjugues associant par liaison covalente un ionophore carboxylique monovalent et une macromolecule et leur utilisation comme agents potentialisateurs des immunotoxines
CA1314245C (en) * 1984-05-23 1993-03-09 Franz Jansen Process for the preparation of conjugates in which a monovalent carboxylic ionophore is associated by means of a covalent bond with a macromolecule, which are useful as immunotoxin potentiators
FR2566271B1 (fr) * 1984-06-20 1986-11-07 Sanofi Sa Nouveaux conjugues cytotoxiques utilisables en therapeutique et procede d'obtention
US4670563A (en) * 1984-06-20 1987-06-02 Sanofi Imidazolides as intermediates for the synthesis of cytotoxic conjugates
FR2573656B1 (fr) * 1984-11-29 1987-02-27 Sanofi Sa Medicament comportant en tant qu'association au moins une immunotoxine et au moins un polymere contenant du mannose
FR2577135B1 (fr) * 1985-02-13 1989-12-15 Sanofi Sa Immunotoxines a longue duree d'action comportant un constituant glycopeptidique inactivant les ribosomes modifie sur ses motifs polysaccharidiques
US4698420A (en) * 1985-02-25 1987-10-06 Xoma Corporation Antibody hybrid molecules and process for their preparation
US4904481A (en) * 1985-04-17 1990-02-27 The Board Of Trustess Of Leland Stanford University Method of conferring immuno-tolerance to a specific antigen
ATE87318T1 (de) * 1985-11-29 1993-04-15 Consolidated Pharmaceuticals L Ricin-antikoerper-konjugate.
EP0252951A4 (en) * 1986-01-06 1988-09-07 Univ Melbourne TECHNETIUM-ANTIBODY CONJUGATES.
US4771128A (en) * 1986-10-10 1988-09-13 Cetus Corporation Method of purifying toxin conjugates using hydrophobic interaction chromatography
US4965392A (en) * 1987-03-26 1990-10-23 Neorx Corporation Chelating compounds for metal-radionuclide labeled proteins
US4981979A (en) * 1987-09-10 1991-01-01 Neorx Corporation Immunoconjugates joined by thioether bonds having reduced toxicity and improved selectivity
US5171563A (en) * 1988-09-30 1992-12-15 Neorx Corporation Cleavable linkers for the reduction of non-target organ retention of immunoconjugates
EP0436664B1 (en) * 1988-09-30 1994-11-09 Neorx Corporation Cleavable linkers for the reduction of non-target organ retention of immunoconjugates
WO2008073160A2 (en) * 2006-08-17 2008-06-19 The Trustees Of Columbia University In The City Of New York Methods for converting or inducing protective immunity

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2437213A1 (fr) * 1978-09-28 1980-04-25 Cm Ind Produits cytotoxiques formes par liaison covalente de la chaine a de la ricine avec un anticorps et leur procede de preparation
JPS5616418A (en) * 1979-07-20 1981-02-17 Teijin Ltd Antitumor protein complex and its preparation
FR2466252A2 (fr) * 1979-10-03 1981-04-10 Clin Midy Nouveaux produits ayant notamment des proprietes anticancereuses a base de chaine a de la ricine et d'une proteine
EP0044167A3 (en) * 1980-07-14 1982-04-21 The Regents Of The University Of California Antibody targeted cytotoxic agent
FR2521010B1 (fr) * 1982-02-09 1985-07-19 Sanofi Sa Medicaments comportant en tant qu'association au moins une immunotoxine et au moins un ionophore carboxylique monovalent
FR2522968B1 (fr) * 1982-03-10 1986-03-28 Sanofi Sa Medicament cytotoxique forme de l'association d'a u moins une immunotoxine et de la chloroquine
FR2536997B1 (fr) * 1982-03-11 1987-08-07 Sanofi Sa Medicaments cytotoxiques comportant au moins une immunotoxine et de la methylamine
US4485093A (en) * 1982-08-13 1984-11-27 Runge Richard G Immunotoxin conjugate which comprises arsanilic acid, useful for treating malignant tumors, particularly pancreatic cancer

Also Published As

Publication number Publication date
FR2516794B1 (fr) 1985-10-25
US4919927A (en) 1990-04-24
EP0080401B1 (fr) 1992-07-29
DE3280408D1 (de) 1992-09-03
CA1209472A (en) 1986-08-12
EP0080401A1 (fr) 1983-06-01
DE3280408T2 (de) 1993-03-04
NZ202563A (en) 1986-04-11
AU561660B2 (en) 1987-05-14
US4643895A (en) 1987-02-17
AU9033482A (en) 1983-05-26
ATE78699T1 (de) 1992-08-15
FR2516794A1 (fr) 1983-05-27
JPS58135821A (ja) 1983-08-12

Similar Documents

Publication Publication Date Title
ZA828048B (en) Novel anti-cancer drugs for the treatment of leukaemias t constituted by the chain a of ricin and a specific monoclonal antibody
IE820815L (en) Anti-cancer drug.
NL7810176A (nl) Gedoseerd farmaceutisch preparaat voor de behandeling van bacterieele infecties, alsmede verpakking voor een of meer doserings-eenheden van dit preparaat.
ATE46084T1 (de) Immunotoxin-konjugate.
NL187516C (nl) Werkwijze voor de bereiding van een proteine-concentraat uit melk dat immunoglobulinen bevat, en geneesmiddel tegen gastro-enteritis.
DE69331761D1 (de) Arzneimittel, die den durch ampa rezeptoren vermittelten synaptischen respons erhöhen
OA05305A (fr) Fermoir pour collier ou équivalent.
CN116528911A8 (zh) 抗cd73抗体、抗体偶联药物及其用途
EP0350690A3 (de) Neutralisation der in vitro- und in vivo-toxischen Eigenschaften von TNF-alfa durch monoklonale Antikörper und die davon abgeleiteten Fragmente
DK0845998T3 (da) Lægemidler til immunbehandling indeholdende antistoffer, der specifikt genkender MHCII-antigenet hos en patient, der skal behandles
ATE175215T1 (de) Arzneimittel für die verlängerte immunsuppression und tumorzellelimination
NO922621L (no) Farmasoeytiske preparater inneholdende antigen-antistoffkomplekser og anvendelser derav
AU2456888A (en) Monoclonal antibodies specific for HIV and hybridomas for their production
ES450601A1 (es) Un procedimiento para la preparacion de nuevos derivados de 4,5-diaril-2-(tiosustituido) michazol.
ATE104860T1 (de) Aktiver wirkstoff und diesen enthaltendes arzneimittel zur verhinderung oder bekaempfung der abstossung von organtransplantaten.
FR2536997B1 (fr) Medicaments cytotoxiques comportant au moins une immunotoxine et de la methylamine
ES2000615A6 (es) Procedimiento para la preparacion del anticuerpo monoclonal designado como mak 436-15 del isotipo igg3"
FR2521010B1 (fr) Medicaments comportant en tant qu'association au moins une immunotoxine et au moins un ionophore carboxylique monovalent
NL186860C (nl) N,n'-bis-(3-picolyl)-4-methoxy-isoftalamidemonohydraat, werkwijze voor de bereiding daarvan en farmaceutische preparaten, die dit bevatten.
KR900005996A (ko) 자기면역 질환의 치료 또는 예방을 위한 면역독소
IT1233005B (it) Anticorpo umano monoclonale, composizione terapeutica che lo contiene linea cellulare capace di produrre l'anticorpo, procedimento per la sua produzione
IT8722631A0 (it) Derivati proteici del ferro altamente biodisponibile e tollerabili, loro preparazione e composizioni farmaceutiche che licontengono.
ATE110786T1 (de) Monoklonaler antikörper gegen exotoxin a von pseudomonas aeruginosa.
FR2900M (fr) Médicament a base de disulfure de bis (n-acéthylhydrazino-n'-carbonylméthyle) pour les traitements des inflammations.
IT8020016A0 (it) Nuovi medicamenti per il trattamento dell'obesita'.